HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Related

466.075

-1.678-0.36%

Number of Gainers:20

Number of Losers:32

Number of Flat:3

PE:- -

High:474.196

Open:467.729

Low:464.409

Close:467.752

Loading ...

Bestzyme's Mellia™ Brazzein Receives FDA "No Questions" Letter, Bringing Creative Sugar Reduction Solution to Global Market

THOMSON REUTERS

Innovent Announces Nmpa Approval of Limertinib, a Third-Generation Egfr Tki Collaborated With Ask Pharma, for the First-Line Treatment of Lung Cancer

THOMSON REUTERS

BRIEF-Zylox-Tonbridge Medical Technology Recommends Distribution Of Final Dividend Of RMB0.1 Per Share

BRIEF-Innovent Biologics Says Third-Generation EGFR TKI Limertinib Received Approval From NMPA

BRIEF-Zylox-Tonbridge Medical Technology Says Intention To Conduct On-Market Share Repurchase

BRIEF-Hansoh Pharmaceutical Receives Drug Registration Approval Of Hengmeida- (Ibrexafungerp Tablets)

Zylox-Tonbridge Medical Technology - Recommends Distribution of Final Dividend of RMB0.1 per Share

THOMSON REUTERS

Zylox-Tonbridge Medical Technology - Intention to Conduct on-Market Share Repurchase to Amount Not Exceeding HKD650 Mln

THOMSON REUTERS

Innovent Biologics - Third-Generation Egfr Tki Limertinib Received Approval From Nmpa

THOMSON REUTERS

Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application for Toripalimab From Nmpa

THOMSON REUTERS

BRIEF-Keymed Biosciences Announces Approval Of IND For Cm518d1 By The National Medical Products Administration Of China

KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

THOMSON REUTERS

KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

THOMSON REUTERS

Everest Medicines to Drop B Marker from Stock Short Name

MT Newswires Live

KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers

THOMSON REUTERS

KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers

THOMSON REUTERS

RPT-ANALYSIS-Tariff-hit China exporters reluctant to heed government calls to sell locally

Vesync's Privatization Gets Nod from Shareholders

MT Newswires Live

BRIEF-JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License

JW (Cayman) Therapeutics - Grants Juno Therapeutics Non-Exclusive License Under Jw Slvv Manufacturing Process, Others

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":466.07452,"timestamp":1745568501401,"preClose":467.7521,"halted":0,"volume":592708408,"delay":0,"changeRate":-0.003586,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-1.677582,"latestTime":"04-25 16:00:00","open":467.72882,"high":474.19583,"low":464.4094,"amount":14876747483,"amplitude":0.020922,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745803800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745544600000,1745553600000],[1745557200000,1745568000000]],"pbRate":2.234092,"peRate":21.950815,"turnoverRate":0.00422,"increases":19,"decrements":31,"flats":3,"marketCap":2621670112960,"floatMarketCap":2056871367104},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":474.19583,"amplitude":0.020922,"preClose":467.7521,"low":464.4094,"pbRate":"2.234092","latestPrice":466.07452,"volume":592708408,"delay":0,"open":467.72882,"prevYearClose":446.93042,"prevWeekClose":463.703,"prevMonthClose":505.776,"prevQuarterClose":505.776,"fiveDayClose":459.33,"twentyDayClose":493.662,"sixtyDayClose":445.14,"secType":"PLATE","market":"HK","turnoverRate":0.00422,"peRate":21.950815,"marketCap":2621670112960,"floatMarketCap":2056871367104,"timestamp":1745568501401,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":20,"down":32,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530788106","title":"Bestzyme's Mellia™ Brazzein Receives FDA \"No Questions\" Letter, Bringing Creative Sugar Reduction Solution to Global Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2530788106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530788106?lang=en_us&edition=fundamental","pubTime":"2025-04-27 09:40","pubTimestamp":1745718032,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250427:nTUA3YXQCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1141","01548","HK0000320223.HKD","BK1583","HK0000320264.USD","HK0000306701.USD","HK0000306685.HKD","BK1576"],"gpt_icon":0},{"id":"2530978951","title":"Innovent Announces Nmpa Approval of Limertinib, a Third-Generation Egfr Tki Collaborated With Ask Pharma, for the First-Line Treatment of Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530978951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530978951?lang=en_us&edition=fundamental","pubTime":"2025-04-26 08:00","pubTimestamp":1745625603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250426:nTUA3RXWQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1969619763.USD","01801","LU2488822045.USD","BK1589","LU2328871848.SGD","BK1583","BK1161"],"gpt_icon":0},{"id":"2530315229","title":"BRIEF-Zylox-Tonbridge Medical Technology Recommends Distribution Of Final Dividend Of RMB0.1 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2530315229","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530315229?lang=en_us&edition=fundamental","pubTime":"2025-04-26 00:31","pubTimestamp":1745598679,"startTime":"0","endTime":"0","summary":"BRIEF-Zylox-Tonbridge Medical Technology Recommends Distribution Of Final Dividend Of RMB0.1 Per ShareApril 25  - Zylox-Tonbridge Medical Technology Co Ltd 2190.HK:RECOMMENDS DISTRIBUTION OF FINAL DIVIDEND OF RMB0.1 PER SHAREFurther company coverage: 2190.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R30D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02190","BK1100","BK1587","BK1583","BK1574"],"gpt_icon":0},{"id":"2530537151","title":"BRIEF-Innovent Biologics Says Third-Generation EGFR TKI Limertinib Received Approval From NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2530537151","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530537151?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:10","pubTimestamp":1745593806,"startTime":"0","endTime":"0","summary":"BRIEF-Innovent Biologics Says Third-Generation EGFR TKI Limertinib Received Approval From NMPAApril 25 (Reuters) - Innovent Biologics Inc 1801.HK:THIRD-GENERATION EGFR TKI LIMERTINIB RECEIVED APPROVAL FROM NMPAFurther company coverage: 1801.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R31PI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU2488822045.USD","LU1969619763.USD","LU2328871848.SGD","BK1583","BK1161","BK1589"],"gpt_icon":0},{"id":"2530539391","title":"BRIEF-Zylox-Tonbridge Medical Technology Says Intention To Conduct On-Market Share Repurchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2530539391","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530539391?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:02","pubTimestamp":1745593348,"startTime":"0","endTime":"0","summary":"BRIEF-Zylox-Tonbridge Medical Technology Says Intention To Conduct On-Market Share RepurchaseApril 25  - Zylox-Tonbridge Medical Technology Co Ltd 2190.HK:INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE TO AMOUNT NOT EXCEEDING HKD650 MILLIONFurther company coverage: 2190.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R30TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1574","BK1583","02190","BK1587"],"gpt_icon":0},{"id":"2530320153","title":"BRIEF-Hansoh Pharmaceutical Receives Drug Registration Approval Of Hengmeida- (Ibrexafungerp Tablets)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530320153","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530320153?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:00","pubTimestamp":1745593219,"startTime":"0","endTime":"0","summary":"BRIEF-Hansoh Pharmaceutical Receives Drug Registration Approval Of Hengmeida- April 25  - Hansoh Pharmaceutical Group Company Ltd 3692.HK:DRUG REGISTRATION APPROVAL OF HENGMEIDA-  WAS GRANTED BY NMPAFurther company coverage: 3692.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R30DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1589","03692","BK1583"],"gpt_icon":0},{"id":"2530133070","title":"Zylox-Tonbridge Medical Technology -  Recommends Distribution of Final Dividend of RMB0.1 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2530133070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530133070?lang=en_us&edition=fundamental","pubTime":"2025-04-25 21:04","pubTimestamp":1745586270,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R30D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1100","BK1574","BK1583","BK1587","02190"],"gpt_icon":0},{"id":"2530813854","title":"Zylox-Tonbridge Medical Technology - Intention to Conduct on-Market Share Repurchase to Amount Not Exceeding HKD650 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2530813854","media":"THOMSON REUTERS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530813854?lang=en_us&edition=fundamental","pubTime":"2025-04-25 20:46","pubTimestamp":1745585190,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R30TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1587","02190","BK1100","BK1583"],"gpt_icon":0},{"id":"2530418258","title":"Innovent Biologics -  Third-Generation Egfr Tki Limertinib Received Approval From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2530418258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530418258?lang=en_us&edition=fundamental","pubTime":"2025-04-25 20:05","pubTimestamp":1745582747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R31PI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU2488822045.USD","BK1589","LU1969619763.USD","BK1583","LU2328871848.SGD","01801"],"gpt_icon":0},{"id":"2530813951","title":"Shanghai Junshi Biosciences -  Approval of Supplemental New Drug Application for Toripalimab From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2530813951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530813951?lang=en_us&edition=fundamental","pubTime":"2025-04-25 19:40","pubTimestamp":1745581251,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R31PE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688180","BK1515","01877","BK1583","BK0239","BK1161"],"gpt_icon":0},{"id":"2530390117","title":"BRIEF-Keymed Biosciences Announces Approval Of IND For Cm518d1 By The National Medical Products Administration Of China","url":"https://stock-news.laohu8.com/highlight/detail?id=2530390117","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530390117?lang=en_us&edition=fundamental","pubTime":"2025-04-25 17:48","pubTimestamp":1745574511,"startTime":"0","endTime":"0","summary":"BRIEF-Keymed Biosciences Announces Approval Of IND For Cm518d1 By The National Medical Products Administration Of China April 25 (Reuters) - Keymed Biosciences Inc 2162.HK:KEYMED BIOSCIENCES ANNOUNCES","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA8MQPDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1587","BK1583","BK1574","02162"],"gpt_icon":0},{"id":"2530097269","title":"KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2530097269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530097269?lang=en_us&edition=fundamental","pubTime":"2025-04-25 17:44","pubTimestamp":1745574260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA6LMCSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1583","BK1587","02162","BK1161"],"gpt_icon":0},{"id":"2530065059","title":"KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2530065059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530065059?lang=en_us&edition=fundamental","pubTime":"2025-04-25 17:24","pubTimestamp":1745573061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA8MQPDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","BK1583","02162","BK1574"],"gpt_icon":0},{"id":"2530905231","title":"Everest Medicines to Drop B Marker from Stock Short Name","url":"https://stock-news.laohu8.com/highlight/detail?id=2530905231","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530905231?lang=en_us&edition=fundamental","pubTime":"2025-04-25 17:20","pubTimestamp":1745572827,"startTime":"0","endTime":"0","summary":"Everest Medicines (HKG:1952) will cease to have the B marker attached to its stock short name from May 2, according to a Friday filing with the Hong Kong bourse.The biopharmaceutical company's new English stock short name will be EVEREST MED.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"2530494268","title":"KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2530494268","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530494268?lang=en_us&edition=fundamental","pubTime":"2025-04-25 11:50","pubTimestamp":1745553039,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA3BP08M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1583","BK1161","02162","BK1587"],"gpt_icon":0},{"id":"2530094451","title":"KeyMed Biosciences Announces Approval of Ind for Cm518d1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2530094451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530094451?lang=en_us&edition=fundamental","pubTime":"2025-04-25 11:37","pubTimestamp":1745552241,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nTUA8DXHL6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","BK1587","BK1161","02162"],"gpt_icon":0},{"id":"2530899035","title":"RPT-ANALYSIS-Tariff-hit China exporters reluctant to heed government calls to sell locally","url":"https://stock-news.laohu8.com/highlight/detail?id=2530899035","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530899035?lang=en_us&edition=fundamental","pubTime":"2025-04-25 07:00","pubTimestamp":1745535600,"startTime":"0","endTime":"0","summary":"RPT-ANALYSIS-Tariff-hit China exporters reluctant to heed government calls to sell locallyRepeats earlier story with no change to textBeijing working to facilitate exporters shift to domestic marketFactories complain about price wars, low profits, payment delaysChina's economy needs more demand, not more supply, say analystsBy Liangping Gao, Ellen Zhang and Casey Hall","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nL1N3R20AM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0051755006.USD","LU0348788117.USD","LU1303224171.USD","LU2097828557.USD","LU0611395673.USD","LU0541501648.USD","09618","LU0918141705.HKD","LU0214875030.USD","SG9999001226.SGD","HMTD.SI","LU0509642566.USD","89618","LU0708995583.HKD","LU2488822045.USD","LU0463099449.HKD","LU1044874839.SGD","IE00BF5LJ272.USD","LU1323998911.USD","JD","LU0244354667.USD","LU0384037296.USD","LU1868838027.USD","LU0067412154.USD","LU1880383440.USD","BK1610","BK1604","LU0823426480.USD","IE0034224299.USD","IE00B0JY6N72.USD","LU0633140727.USD","LU2097828714.EUR","LU0345775950.USD","LU0594300419.USD","BK1583","LU1023057109.AUD","LU1282648689.USD","LU0084288322.USD","LU0456827905.SGD","LU1224709979.USD","LU0307460666.USD","LU0163747925.USD","LU0326948709.USD","LU1688375341.USD","LU0128522157.USD","LU0261950983.USD","LU0588545490.SGD","SG9999002463.SGD"],"gpt_icon":1},{"id":"2529760052","title":"Vesync's Privatization Gets Nod from Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2529760052","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529760052?lang=en_us&edition=fundamental","pubTime":"2025-04-24 19:19","pubTimestamp":1745493593,"startTime":"0","endTime":"0","summary":"Shareholders of Vesync  voted in favor of the company's privatization by Victory III at an extraordinary general meeting held on April 23, Wednesday.The proposal will be heard in court on May 1. The court ruling is the last condition needed for the go-private deal to become effective, expected to take place on May 7, according to a bourse filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02148","BK1583","BK1214","BK1557"],"gpt_icon":0},{"id":"2529538145","title":"BRIEF-JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License","url":"https://stock-news.laohu8.com/highlight/detail?id=2529538145","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529538145?lang=en_us&edition=fundamental","pubTime":"2025-04-22 23:03","pubTimestamp":1745334225,"startTime":"0","endTime":"0","summary":"BRIEF-JW  Therapeutics Grants Juno Therapeutics Non-Exclusive LicenseApril 22  - JW  Therapeutics Co Ltd 2126.HK:GRANTS JUNO THERAPEUTICS NON-EXCLUSIVE LICENSE UNDER JW SLVV MANUFACTURING PROCESS, OTHERSFurther company coverage: 2126.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R00WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","02126","BK1574"],"gpt_icon":0},{"id":"2529587025","title":"JW (Cayman) Therapeutics - Grants Juno Therapeutics Non-Exclusive License Under Jw Slvv Manufacturing Process, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2529587025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529587025?lang=en_us&edition=fundamental","pubTime":"2025-04-22 22:44","pubTimestamp":1745333076,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R00WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","BK1161","02126"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":58,"code":"91000000","status":"200"}]}}